聚丙交酯复合乙交酯微球经肝动脉化疗栓塞术治疗肝癌的动物实验

目的：在肝细胞癌动物模型上观察聚丙交酯复合乙交酯（PLcG)微球经肝动脉化疗栓塞术（TACE）治疗肝癌的疗效。方法：在雄性ACI大鼠（15例）肝包膜下植入Morris Hepatoma 3924A肝癌小瘤块（1mm3)，移植术中13天时行磁共振检查，再经正中腹切开术和经胃十二指肠动脉逆行插管进行以下介入治疗：治疗组A（40mg PLcG 0.05mg丝裂霉素，4例），对照组B（0．05mg丝裂霉素＋0．04mg碘化油＋肝动脉结扎，4例）和对照组C（1．5ml生理盐水，7例），插管术后13天再次行磁共振术观察肝肿瘤体积变化。结果：在C组，肿瘤体积在实验期间增长27．12倍，在B组，肿瘤体积增长3．76倍，而在A组，肿瘤体积仅增长2．87倍。A组与C组肿瘤体积增长率在t检验时均有显著性差异（P＜0．05），结论：在动物实验中将PLcG微球运用于TACE可明显抑制肝肿瘤生长。

An experimental study on the therapeutic effects of Poly-Lactid-co-Glycolid(PLcG)-microspheres in the transarterial chemoembolization (TACE)

Objective:To evaluate the therapeutic effects of PLcG microspheres in the TACE in an animal model of hepatocellular carcinoma(HCC).Methods:The subcapsular implantation of a solid Morris Hepatoma 3924A (1mm 3) in the left liver was carried out at 15 male ACI rats.13 days after the implantation, the volume of tumor was measured by MRI.A laparotomy was then performed and after retrograde catheterization of the gastroduodenal artery the following protocols were carried out:(A) 40 mg PLcG +0.05 mg mitomycin (n=4);(B) 0.05 mg mitomycin+0.04 mg Lipiodol +ligation (n=4);(C) 0.9% NaCl (n=7).13 days after the injection of the materials mentioned previously, the change in the volume of tumor was determined by MRI again.Results:An obvious growth in the volume of tumor with 27.12 times in group C, with 3.76 times in group B,but a slight growth with only 2.87 times in the treated group (group A) were observed.There was a significant difference of the change in the volume of tumor between group A and group C by t test ( P <0.05).Conclusion:The growth of HCC could be inhibited using PLcG microspheres in the TACE in animal model.